Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


GREY:BIOAF - Post by User

Comment by prophetoffactzon Feb 09, 2023 8:30am
84 Views
Post# 35276566

RE:Does Bioasis have a responsibility to update Shareholders?

RE:Does Bioasis have a responsibility to update Shareholders?The company is presumably in intense multi-party negotiations towards some kind of resolution. Forcing it to cough up information in this time period to those it is negotiating against could be like handcuffing it. Negotiations can be difficult to fully understand in the best of times given the posturing until a deal is signed.

Potentially without a data package for its lead xB3 program as Hunter data was expected in Q2 2023 and is potentially years from clinical trials it will be interesting to see what happens as BTI attemps to address immediate material debt and create a cash runway to material events. Hunter itself is years behind Denali's Hunter program which is in trials with a big lead-to-market. Focus would appear on BTI's new EGF assets which appear to have visibility to clinical trials as they are said Phase II ready.

The Biodexa plan sure had a lot more appeal than the visibility in the current situation.

How about a $10 million financing at $.025 with a full warrant with an acceleration clause for 800 million 800 million new shares? 

<< Previous
Bullboard Posts
Next >>